NutriBand (NTRB) Liabilities and Shareholders Equity (2016 - 2026)
NutriBand (NTRB) posted Liabilities and Shareholders Equity of $6.9 million for Q2 2026, down 8.69% sequentially from $7.5 million in Q1 2026, and up 12.03% YoY from $6.2 million in Q2 2025.
NutriBand (NTRB) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
NutriBand has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $6.9 million in Q2 2026.
- Quarterly Liabilities and Shareholders Equity rose 12.03% year-over-year to $6.9 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $33.0 million (down 16.99% YoY) and the FY2026 annual result came in at $7.5 million, up 1.04% from the prior year.
- Liabilities and Shareholders Equity slipped to $6.9 million in Q2 2026 per NTRB's latest filing, from $7.5 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $15.2 million in Q2 2024 and troughed at $6.2 million in Q2 2025.
- A 5-year average of $9.9 million and a median of $9.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 74.68% in 2024, then tumbled 59.4% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $10.7 million in 2022, then decreased by 20.12% to $8.5 million in 2023, then jumped by 47.17% to $12.5 million in 2024, then slumped by 32.88% to $8.4 million in 2025, then fell by 18.14% to $6.9 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $6.9 million, $7.5 million, and $8.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 6.89 Mn |
| Jan 31, 2026 | 7.55 Mn |
| Oct 31, 2025 | 8.42 Mn |
| Jul 31, 2025 | 10.18 Mn |
| Apr 30, 2025 | 6.15 Mn |
| Jan 31, 2025 | 7.47 Mn |
| Oct 31, 2024 | 12.54 Mn |
| Jul 31, 2024 | 13.63 Mn |
| Apr 30, 2024 | 15.15 Mn |
| Jan 31, 2024 | 7.52 Mn |
| Oct 31, 2023 | 8.52 Mn |
| Jul 31, 2023 | 9.87 Mn |
| Apr 30, 2023 | 8.68 Mn |
| Jan 31, 2023 | 9.46 Mn |
| Oct 31, 2022 | 10.67 Mn |
| Jul 31, 2022 | 11.39 Mn |
| Apr 30, 2022 | 11.98 Mn |
| Jan 31, 2022 | 12.74 Mn |
| Oct 31, 2021 | 15.43 Mn |
| Jul 31, 2021 | 10.16 Mn |